The Cancer Prevention and Research Institute of Texas (CPRIT) recently awarded grants to six faculty members at UT Austin, including the Division of Chemical Biology and Medicinal Chemistry's Kevin Dalby, Ph.D. for his Targeted Therapeutic Drug Discovery and Development Program.
Combining mobile health technology, or mHealth, and community outreach to improve the health outcomes of people experiencing homelessness is the target of a new study led by Division of Health Outcomes Associate Professor Leticia Moczygemba, Pharm.D., Ph.D., thanks to a five-year research grant from the U.S. Department of Health and Human Services Agency for Healthcare Research and Quality.
Three researchers from the College of Pharmacy won an award from the Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation. Leticia R. Moczygemba, Pharm.D., Ph.D., Carolyn M. Brown, Ph.D. and Michael Johnsrud, Ph.D., R.Ph. were awarded $5,000 from the PhRMA Foundation for their proposal to advance racial and ethnic representation in value assessments.
Molecular Pharmaceutics and Drug Delivery Professor Maria A. Croyle, Ph.D. received extensive coverage in the March 2021 edition of Texas Monthly regarding her innovative peelable film drug delivery research. Among its many potential applications, Dr. Croyle’s technology could deliver COVID-19 vaccines through a small oral strip, without need for refrigeration or extensive storage and transportation infrastructure.
Molecular Pharmaceutics and Drug Delivery professor Maria A. Croyle R.Ph., Ph.D. earned 2021’s David Lehr Research Award from the American Society for Pharmacology and Experimental Therapeutics (ASPET). Dr. Croyle will receive research funding to investigate novel regulatory mechanisms of drug metabolism in the context of active infection with SARS-CoV-2 and after recovery.
The newly-formed Jurata Thin Film will work to bring Dr. Maria Croyle's thin film technology to market, allowing biologics and vaccines to be packaged, shipped, and stored at room temperature for extended periods of time.
Researchers in the lab of Dr. Hugh D.C. Smyth have released promising results of a new method to treat SARS-CoV-2, the coronavirus that causes COVID-19. The antiviral niclosamide, when incorporated with human lysozyme as a carrier molecule, shows potential as an effective COVID-19 treatment when delivered directly to the airways.